1 / 13

IDF EUROPE GA MEETING MUNICH,2005

IDF EUROPE GA MEETING MUNICH,2005. SURVEY ON DIABETES CARE IN EIGHT CENTRAL EASTERN EUROPEAN COUNTRIES (THE DEPAC STUDY). Survey of diabetes care in eight new EU accessing countries.

shantell-allen
Download Presentation

IDF EUROPE GA MEETING MUNICH,2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IDF EUROPE GA MEETINGMUNICH,2005 SURVEY ON DIABETES CARE IN EIGHT CENTRAL EASTERN EUROPEAN COUNTRIES (THE DEPAC STUDY)

  2. Survey of diabetes care in eight new EU accessing countries • Planned and organized by the Diabetes Experts’ Panel from Accessing Countries (DEPAC) established in May 2004 • PROTOCOL A multi-centre, randomised, non-interventional survey assessing metabolic control, short- and long term complications, and diabetes care of patients in 8 EU accessing countries

  3. Timelines of the survey(Critical milestones) • Preparations phase • Final protocol approved 22 Oct 2004 • Translation of protocol into local languages 5 Nov • Investigators’ meetings in countries 19 Nov–17 Dec • Operations phase • Collection of data started 03 Jan 2005 • Collection of data completed 28 Feb • Analysis phase • Statistical analysis complete 20 March • Integrated survey report complete (abstract to EASD) 28 March

  4. Number of patients (planned:10 000; collected:11 085) EST 200 HU 1800 LAT 300 CZ 2000 LIT 300 SLO300 SK 1100PL 4000

  5. CLASSIFICATION • Type 1 DM: 2497 22.85% • Type 2 DM: 8231 75.31% • Other Types of DM: 202 1.84%

  6. AGE AND DIABETES DURATION • Mean age (years): Type 1 men:37,07 Type 2:61,08 women: 36,7063,17 • Diabetes duration (years): Type 1 men: 13,21 Type 2 :9,61 women: 14,3710,68

  7. INSULIN TREATMENT • Human insulins: Type 1 DM: 70.10% Type 2 DM: 40.50% • Analog insulins: Type 1 : 49.03% Type 2 : 10.82%

  8. ORAL TREATMENT • Metformin Sulphonyloureas Type 2 DM: 50.70%39.0% • AcarboseOral + Insulin Type 2 : 10.0%14.20%

  9. Results: metabolic control and lipids • Poor metabolic control (HbA1c > 8%) Type 1 DM: 49.10% Type 2 DM: 36.77% • Dyslipidemia (high serum lipids) Type 1 : 29.03% Type 2 : 66.82%

  10. Results: microvascular complications • Retinopathy Type 1 : 41.30% Type 2 : 32.34% • Nephropathy Type 1 : 28.46% Type 2 : 25.02% • Neuropathy Type 1 : 31.79% Type 2 : 30.22%

  11. Results: cardiovascular complications • Hypertension Type 1 : 30.52% Type 2 : 79.49% • Cardiovascular disease Type 1 : 8.58% Type 2 : 43.34%

  12. SURVEY ANALYSIS The only differences in diabetic complications between men and women which reached statistically significant levels were: • hypertension (P<0.01), • myocardial infarction (P<0.001), • peripheral arterial disease (P<0.001) • and diabetic foot ulcer (P<0.001)

  13. CONCLUSIONS The results should be a platform for further goals on country and EU levels: • highlighting the costs and benefits from diabetes treatment, • creating ways of health promotion and health monitoring, • increasing patient empowerment through education , - discussion about the status of National Diabetes Programmes in each countries.

More Related